Status:
COMPLETED
Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Diabetes Mellitus Type 2
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
This study is designed to assess the potential difference in Fasting Plasma Glucose (FPG) lowering efficacy between the two DPP-4 inhibitors vildagliptin and sitagliptin, both after a two weeks treatm...
Eligibility Criteria
Inclusion
- Patients with type 2 diabetes 18 to 85 years Metformin monotherapy \> 4 weeks HbA1c 6.5 - 9.5%
Exclusion
- FPG \> 270 mg/dl Use of other antidiabetic drugs than metformin major cardiovascular event in the last 6 months (MI, stroke…)
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
187 Patients enrolled
Trial Details
Trial ID
NCT01398592
Start Date
June 1 2011
End Date
June 1 2012
Last Update
February 12 2013
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Bad Oeynhausen, Germany, 32549
2
Novartis Investigative Site
Berlin, Germany, 12347
3
Novartis Investigative Site
Berlin, Germany, 13597
4
Novartis Investigative Site
Berlin, Germany, 14089